We compared the efficacy and toxicity profiles of candidate drugs in RB1-deficient and MYCN-amplified RB organoids and in retinal organoids derived from human embryonic stem cells (hESCs) with those of clinically used anticancer drugs. Here, RB1 is linked to retinoblastoma.